These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30109169)

  • 1. Characterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells.
    Kamli H; Glenda GC; Li L; Vesey DA; Morais C
    J Kidney Cancer VHL; 2018; 5(3):1-9. PubMed ID: 30109169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
    Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
    Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways.
    Gobe GC; Ng KL; Small DM; Vesey DA; Johnson DW; Samaratunga H; Oliver K; Wood S; Barclay JL; Rajandram R; Li L; Morais C
    Biochem Biophys Res Commun; 2016 Apr; 473(1):47-53. PubMed ID: 26995091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NGAL can alternately mediate sunitinib resistance in renal cell carcinoma.
    Yu DS; Wu CL; Ping SY; Huang YL; Shen KH
    J Urol; 2014 Aug; 192(2):559-66. PubMed ID: 24423438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma.
    Sekino Y; Sakamoto N; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
    Oncology; 2019; 97(3):164-172. PubMed ID: 31195398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
    Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
    Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody.
    Mizutani Y; Bonavida B; Koishihara Y; Akamatsu K; Ohsugi Y; Yoshida O
    Cancer Res; 1995 Feb; 55(3):590-6. PubMed ID: 7834629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of epithelial-mesenchymal transition via activation of epidermal growth factor receptor contributes to sunitinib resistance in human renal cell carcinoma cell lines.
    Mizumoto A; Yamamoto K; Nakayama Y; Takara K; Nakagawa T; Hirano T; Hirai M
    J Pharmacol Exp Ther; 2015 Nov; 355(2):152-8. PubMed ID: 26306766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic activity of sunitinib and everolimus in Caki-1 renal cancer cells is accompanied by modulations in the expression of apoptosis-related microRNA clusters and BCL2 family genes.
    Papadopoulos EI; Yousef GM; Scorilas A
    Biomed Pharmacother; 2015 Mar; 70():33-40. PubMed ID: 25776476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
    Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
    PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of netrin-1 in metastatic renal cell carcinoma treated with sunitinib.
    Frees S; Zhou B; Han KS; Tan Z; Raven P; Wong A; D'Costa N; Fazli L; Struss W; Moskalev I; Chavez-Munoz C; So A
    Oncotarget; 2018 Apr; 9(32):22631-22641. PubMed ID: 29854303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma.
    Tran TA; Leong HS; Pavia-Jimenez A; Fedyshyn S; Yang J; Kucejova B; Sivanand S; Spence P; Xie XJ; Peña-Llopis S; Power N; Brugarolas J
    Mol Cell Biol; 2016 Jul; 36(13):1836-55. PubMed ID: 27141054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lefty A is involved in sunitinib resistance of renal cell carcinoma cells via regulation of IL-8.
    Cui N; Han Q; Cao Q; Wang K; Zhou X; Hou P; Liu C; Chen L; Xu L
    Biol Chem; 2021 Sep; 402(10):1247-1256. PubMed ID: 34363384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Artesunate Inhibits Growth of Sunitinib-Resistant Renal Cell Carcinoma Cells through Cell Cycle Arrest and Induction of Ferroptosis.
    Markowitsch SD; Schupp P; Lauckner J; Vakhrusheva O; Slade KS; Mager R; Efferth T; Haferkamp A; Juengel E
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33121039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hispidulin potentiates the antitumor effect of sunitinib against human renal cell carcinoma in laboratory models.
    Gao H; Jiang Q; Han Y; Peng J; Wang C
    Cell Biochem Biophys; 2015 Mar; 71(2):757-64. PubMed ID: 25260394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
    Miyazaki A; Miyake H; Fujisawa M
    Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma.
    Miyake M; Anai S; Fujimoto K; Ohnishi S; Kuwada M; Nakai Y; Inoue T; Tomioka A; Tanaka N; Hirao Y
    Oncol Lett; 2012 Jun; 3(6):1195-1202. PubMed ID: 22783417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
    Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
    Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPARα mediates sunitinib resistance via NF-κB activation in clear cell renal cell carcinoma.
    Aimudula A; Nasier H; Yang Y; Zhang R; Lu P; Hao J; Bao Y
    Int J Clin Exp Pathol; 2018; 11(5):2389-2400. PubMed ID: 31938351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.